Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | EDNRA | P25101 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 14/20 | 0.80 |
| ▸ | RXRA | P19793 | 6/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | DRD1 | P21728 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exisulind SCHEMBL25371 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL1651133 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL29395528 | 1.00 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL9711060 | 0.99 | CYP1A2 (0.98) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7634644 | 0.99 | CYP1A2 (0.98) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL24101477 | 0.91 | PPARG (0.84) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL30095195 | 0.91 | PPARG (0.84) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL20158513 | 0.91 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7634637 | 0.91 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7634632 | 0.91 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | claimed |
| EP-1146866-A4 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1146866-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | claimed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | claimed |
| WO-2000044372-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| US-6025394-A | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols | CELL PATHWAYS, INC. (US) | 2000-02-15 | — | — | US | claimed |
| US-4423075-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | claimed |
| CN-111886226-B | Compounds, anti-inflammatory agents containing the same, and cyclooxygenase-2 inhibitors | 张用敏 | 2023-08-15 | — | — | CN | disclosed |
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9889145-B2 | Methods to treat infections | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | disclosed |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-5093356-A | Antiallergens, antiasthma, antiinflammatory, cytoprotective | MERCK FROSST CANADA, INC. (CA) | 1992-03-03 | — | — | US | disclosed |
| US-4423075-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | disclosed |
| US-4423075-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | disclosed |
| US-4423075-A | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid | AYERST, MCKENNA & HARRISON INC. (CA) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180066004-A9 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | CYP1A2 719/4885MAPT 1548/4885MAPK1 4158/4885 |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | CYP1A2 797/4885MAPT 583/4885MAPK1 4258/4885 |
| US-20170037071-A1 | MITOCHONDRIA-TARGETING PLATINUM(IV) PRODRUG | MT-ND4, MT-CO3, COX6A1 | CYP1A2 719/4885MAPT 1548/4885MAPK1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.